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Rituximab Mediates a Strong Elevation of
B-Cell-Activating Factor Associated with Increased
Pathogen-Specific IgG but Not Autoantibodies in
Pemphigus Vulgaris
Angela Nagel1, Eva Podstawa1, Markus Eickmann2, Hans-Helge Mu¨ller3, Michael Hertl1 and Ru¨diger Eming1
Pemphigus vulgaris (PV) is a severe autoimmune disease affecting the skin and mucous membranes,
characterized by autoantibodies mainly against desmoglein 3 (dsg3). This study investigated the effects of
different treatment options on two B-cell mediators, B-cell-activating factor (BAFF) and a proliferation-inducing
ligand (APRIL), in 19 PV patients on immunosuppressive drugs alone or in combination with immunoadsorption
and anti-CD20 antibody, respectively. Serum BAFF and APRIL levels, circulating desmoglein-reactive
autoantibodies, and serum IgG specific for varicella-zoster virus (VZV) and Epstein–Barr virus (EBV) were
determined by ELISA before and at different time points after initiation of the respective therapy. In contrast to
immunosuppressive therapy alone and in combination with adjuvant immunoadsorption, respectively,
rituximab treatment led to a strong and significant elevation of BAFF, but not of APRIL levels, which normalized
upon recovery of peripheral CD19þ B cells. Moreover, rituximab treatment led to a statistically significant
increase of anti-VZV-IgG and anti-EBV-IgG titers, whereas anti-dsg1 and -3 specific autoantibody titers decreased
significantly. Our results suggest that elevated BAFF levels might exert a differential effect on the induction of
autoreactive versus pathogen-specific IgG antibody production in PV patients, possibly due to promotion of
antibody release of pathogen-specific long-lived plasma cells.
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INTRODUCTION
Pemphigus vulgaris (PV) is a severe, potentially life-threaten-
ing autoimmune bullous disease primarily characterized by
extensive blisters and erosions of the mucous membranes and
the skin. IgG autoantibodies (autoab) against the desmosomal
adhesion proteins desmoglein 3 (dsg3) and dsg1 have been
shown to induce acantholysis of epidermal keratinocytes, a
hallmark of PV (Amagai, 1999; Payne et al., 2004). Although
immunosuppressive medication including high-dose systemic
glucocorticoids is commonly applied, PV remains a ther-
apeutical challenge. Adjuvant settings, such as immunoad-
sorption (IA) and more recently the monoclonal anti-CD20
antibody rituximab, have been successfully introduced for the
treatment of severe and recalcitrant PV (Eming and Hertl,
2006; Eming et al., 2007). Rituximab induces long-term
clinical remission that is presumably due to depletion of
autoreactive memory B cells as progenitors of autoab-
secreting plasma cells (PC) (Ahmed et al., 2006; Joly et al.,
2007). Accordingly, rituximab has probably a major impact
on the crucial factors for growth and survival of B
lymphocytes, including the B-cell-activating factor of the
TNF family (BAFF) and a proliferation-inducing ligand
(APRIL). BAFF and APRIL are mostly produced by antigen-
presenting cells including dendritic cells and macrophages,
monocytes, and, to a lesser extent, T cells. Moreover, BAFF is
constitutively expressed by stromal cells of spleen, lymph
nodes, and bone marrow (Dillon et al., 2006; Sutherland
et al., 2006; Mackay et al., 2007), determining the size of the
peripheral B-cell pool, whereas inducible BAFF produced by
myeloid and other cells supports the local survival of B
lymphocytes (Schneider, 2005). Recent studies demonstrate
that upregulation of BAFF expression in vivo results in the
rescue of self-reactive, otherwise eliminated B-cell clones as
survival of autoreactive B cells is more dependent upon BAFF
than is the survival of non-autoreactive B cells (Lesley et al.,
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2004; Thien et al., 2004). Considering its function, BAFF acts
as a key factor controlling B-cell survival and maturation
(Mackay and Leung, 2006), but not proliferation (Mackay
et al., 2003), and plays an important role in enforcing B-cell
self-tolerance (Mackay et al., 2007). BAFF and APRIL
promote an immunoglobulin switch to the IgG, IgE, and IgA
subclasses (Litinskiy et al., 2002; Bossen and Schneider,
2006). B-cell maturation antigen (BCMA), a receptor pre-
ferentially expressed on plasmablasts and PC (Avery et al.,
2003), is important for the survival of long-lived bone-
marrow PC (O’Connor et al., 2004), although it is not yet
known whether BAFF or APRIL is critically involved in this
process (Dillon et al., 2006).
It is noteworthy that systemic lupus erythematosus (SLE)
and rheumatoid arthritis (RA) are characterized by over-
expression of BAFF (SLE) or APRIL (RA), which has been
shown to be unaffected by immunosuppressive therapy
(Vallerskog et al., 2006). In contrast, recent studies in PV
did not detect significant differences in serum BAFF and
APRIL levels before or after immunosuppressive treatment in
comparison to healthy controls (Asashima et al., 2006;
Matsushita et al., 2007; Watanabe et al., 2007). Remarkably,
several studies showed an induction of BAFF, but not of
APRIL, in patients with SLE, RA (Vallerskog et al., 2006), and
primary Sjo¨gren’s syndrome (Seror et al., 2007) on rituximab
treatment.
The aim of the current observational study was to
investigate the impact of rituximab-induced B-cell depletion
on serum BAFF and APRIL levels in patients with PV.
Moreover, serum BAFF and APRIL concentrations were
compared to titers of circulating dsg3-specific IgG autoab
and varizella-zoster virus (VZV)- and Epstein–Barr virus
(EBV)-IgG, respectively. Our findings suggest that elevated
BAFF levels might exert a differential effect on the induction
of autoreactive versus pathogen-specific antibody production
in PV.
RESULTS
Induction of BAFF serum levels in PV patients on
immunosuppression and rituximab, but not on
immunosuppression alone or in combination with adjuvant IA
Figure 1a demonstrates serum BAFF levels in three groups of
PV patients, on immunosuppressive therapy alone or on
immunosuppressive therapy with adjuvant rituximab or IA.
Apparently, there were no differences in serum BAFF levels
between the pre-treatment values of the three patient groups
and of healthy controls. In contrast to PV patients treated with
immunosuppressive drugs (IS) alone or in combination with
IA, who did not show any significant alterations in serum
BAFF levels over an observation period of at least 90 days
(Friedman’s test, IS: P¼ 0.323; IA: P¼0.118), treatment with
IS plus rituximab (Rtx) resulted in a pronounced and
significant elevation of serum BAFF levels beginning im-
mediately 1 month after therapy (Wilcoxon’s signed rank test,
P¼0.003) and lasting for up to 12 months after therapy
(Wilcoxon’s signed rank test, Pp0.007).
Differences in BAFF levels in the three groups of patients
before initiation of the respective therapy (d0) did not reach
statistical significance (Kruskal–Wallis test, P¼ 0.139). In
contrast, owing to a strong elevation of circulating BAFF in
PV patients on Rtx, patients on different treatment options
showed a statistically significant disparity in BAFF 1 month
after therapy (Kruskal–Wallis test, P¼0.0004). At this time
BAFF levels of patients on IS and IA were not significantly
different (Mann–Whitney U-test, P¼0.792), whereas PV
patients treated with IS and adjuvant Rtx exhibited statisti-
cally significant differences compared to pooled data of
patients treated with IS alone or with IS and adjuvant IA
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Figure 1. Serum levels of BAFF and APRIL in pemphigus vulgaris (PV)
patients on three different treatment schedules. Serum BAFF (a) and APRIL
(b) levels were analyzed in three different groups of PV patients. The first
group of patients was treated with immunosuppressive drugs only (IS) and the
second group was treated with immunosuppressives and adjuvant
immunoadsorption (IA). Neither of these two groups showed significant
alterations in BAFF or APRIL serum levels over the entire observation period
(Friedman’s test, P40.05). The third group of patients was treated with
immunosuppressives and rituximab (Rtx). Although serum levels of APRIL
remained unchanged over the observation period of 12 months, BAFF levels
were strongly and significantly elevated already 1 month (d60) after rituximab
treatment, which continued up to 12 months (d390) after therapy (Wilcoxon’s
signed rank test, Pp0.007). In contrast to comparative analysis before
treatment, comparison of BAFF levels between the three groups of patients 1
month after the respective therapy showed statistically significant differences
(Kruskal–Wallis test, P¼ 0.0004) due to strong elevation of BAFF after
rituximab-induced B-cell depletion at this time. Design of box plot:
box—50% of data, whiskers—extend from highest to lowest values,
black points—outliers. For box plot and scatter plot: lines—median.
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(Mann–Whitney U-test, Po0.0001). Of note, the separate P-
values of IS versus Rtx and IA versus Rtx, respectively, are
P¼0.0005 and P¼ 0.0002 (Mann–Whitney U-test).
As illustrated in Figure 1b, in contrast to BAFF, APRIL
serum levels were not significantly different between the
three groups of PV patients, neither before the respective
treatment (Kruskal–Wallis test, P¼ 0.431) nor at the primary
end point, 1 month after therapy (Kruskal–Wallis test,
P¼0.349). Furthermore circulating levels of APRIL were
not considerably altered over the entire observation period,
neither on IS alone (Friedman’s test, P¼0.519) nor in
combination with either IA (Friedman’s test, P¼0.985) or
Rtx (Friedman’s test, P¼ 0.268).
These results apparently suggest that the dramatic induc-
tion of serum BAFF levels was due to Rtx treatment, because
systemic immunosuppressives alone or in combination with
adjuvant IA did not show any effect on BAFF. The BAFF-
inducing effect of Rtx treatment is illustrated in a representa-
tive patient (PV7), who initially received IA and subsequently
Rtx treatment (Figure S1a).
Inverse correlation of BAFF serum levels and peripheral CD19þ
B cells after B-cell depletion
Figure 2a summarizes the strong inverse correlation between
the numbers of peripheral CD19þ B cells and serum BAFF
levels of 11 studied PV patients on Rtx treatment. Rituximab
led to a pronounced and significant increase in BAFF serum
levels once B cells were depleted (Wilcoxon’s signed rank
test, P¼0.003), which remained elevated until recurrence of
peripheral B cells (repopulation) (Wilcoxon’s signed rank test,
P¼0.028). Upon restoration of pre-treatment values of
peripheral B-cell numbers (recovery), serum BAFF levels
decreased to pre-treatment levels (‘‘baseline’’) again in the
studied PV patients (Figure 2a). It is noteworthy that Rtx-
induced B-cell depletion did not affect serum APRIL levels
(Figure 2b).
In this regard Figure 3 illustrates the correlation of
peripheral CD19þ B cells and serum levels of the B-cell
activating factors BAFF (Figure 3a) and APRIL (Figure 3b).
Each line represents the data of an individual Rtx-treated PV
patient. Shown is the inverse relationship between circulating
BAFF levels and peripheral CD19þ B cells (expressed as % of
total lymphocytes), that is, decreasing B-cell numbers cause
increasing serum BAFF levels. This correlation was not seen
between APRIL serum levels and peripheral C19þ B-cell
numbers (Figure 3b).
B-cell depletion promotes raised titers of pathogen-specific but
not of autoreactive IgG antibodies in PV patients
One goal of the present study was to investigate the influence
of different treatment options on (auto) antibody production
in PV. In patients on IS alone (Figure 4a) or in combination
with IA (Figure 4b), there was a decline in dsg3-specific IgG
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Figure 2. Effect of rituximab (Rtx) on B-cell-activating factor (BAFF) and a
proliferation-inducing ligand (APRIL) serum levels in PV patients. Shown are
median±range of serum BAFF (a) and APRIL (b) levels in 11 pemphigus
vulgaris (PV) patients in relation to relative numbers of peripheral B cells
(x-axis). BAFF serum levels were strongly and significantly elevated with
highest amounts of BAFF measured after B-cell depletion. This statistically
significant elevation of BAFF persisted until the time of B-cell repopulation,
defined as recurrence of B cells in peripheral blood (that is, X1% CD19þ B
cells, calculated as % of total lymphocytes) (a). At the time of B-cell recovery,
characterized by reaching pre-treatment numbers again, BAFF levels returned
to baseline. Using Wilcoxon’s signed rank test, statistically significant changes
compared with pre-treatment values are illustrated above the related box
plots. APRIL levels remained unchanged on rituximab-induced B-cell
depletion (b). Design of box plot: box—50% of data, center lines—median,
whiskers —extend from highest to lowest values, points—outliers, asterisks—
extreme values.
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Figure 3. Inverse correlation of B-cell-activating factor (BAFF) levels and
peripheral CD19þ B cells. BAFF serum levels and relative numbers of
peripheral CD19þ B cells (expressed as % of total lymphocytes) showed an
inverse correlation (a). In contrast, APRIL levels and peripheral B-cell numbers
(b) were not directly related to each other. Illustrated are data of the 11
patients before and during the entire observation period of 12 months (d0,
d60, d120, d210, d390) after rituximab treatment, whereas each line
represents the data of these time points for one individual patient.
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autoab (Figure 4a and b, left row), associated with clinical
remission as illustrated in Table S1. In contrast, serum
concentrations of anti-VZV-IgG and anti-EBV-IgG were not
significantly changed during the entire observation period in
both groups of PV patients. As expected, IA treatment led to a
strong and transient reduction in both pathogen-specific and
autoreactive IgG due to the dramatic removal of circulating
total IgG from the patients’ plasma (d4, Figure 4b). To analyze
the potential effect of Rtx-induced B-cell depletion on
antibody production, we studied the serum titers of dsg1-
and dsg3-specific IgG autoab and those of VZV- and EBV-
reactive IgG in Rtx-treated PV patients. Figure 4c demon-
strates that anti-dsg3-IgG titers decreased slowly but
continuously, starting 3 months (d120) after Rtx treatment,
finally leading to 20–30% of the pre-treatment values 12
months after B-cell depletion (Figure 4c, left; Wilcoxon’s
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Figure 4. Effect of different treatment schedules on autoreactive versus pathogen-specific antibody titers. Illustrated is the change in desmoglein 3 (dsg3)-
specific autoantibodies (left row), anti-VZV-IgG (center row), and anti-EBV-IgG (right row) in the sera of PV patients over the entire observation period of
immunosuppressive treatment (a), immunosuppressives and immunoadsorption (b), and immunosuppressives and rituximab (c). Although there is a decrease in
dsg3-reactive autoantibodies in each group (Figure 4, left row), pathogen-specific anti-VZV-IgG and anti-EBV-IgG antibodies were not influenced by
immunosuppressives alone (a, center and right) and only transiently reduced, owing to intense removal of total IgG from plasma, by immunoadsorption (b,
center and right). In contrast, there was a statistically significant increase in serum anti-VZV-IgG (c, center) and anti-EBV-IgG (c, right) up to 6 months after
rituximab. Using Wilcoxon’s signed rank test, statistical significance compared to pre-treatment values is presented above the respective box plots. Design of
box plot: box—50% of data, center lines—median, whiskers—extend from highest to lowest values, points—outliers, asterisks—extreme values. Serum titers of
anti-EBV-IgG were available only for 8 of 11 rituximab-treated PV patients (c, right).
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signed rank test, P¼0.005). In 6 of the 11 PV patients, serum
autoab titers against dsg1 were also detectable before Rtx
treatment. Along with a decrease in serum anti-dsg3 autoab
titers there was a decline of dsg1-specific IgG from a median
of 168Uml1 before therapy to a median of 16Uml1 6
months after treatment (data not shown). In contrast, there
was a statistically significant increase in VZV- and EBV-
specific IgG antibodies in the sera of all investigated PV
patients up to 6 months after Rtx therapy (Figure 4c;
Wilcoxon’s signed rank test, Pp0.041 (VZV), Pp0.025
(EBV)). Between 6 and 12 months after Rtx, the titers of
pathogen-specific IgG went back to baseline levels again
(Figure 4c, center and right, Wilcoxon’s signed rank test,
P¼0.374 (VZV), P¼ 0.208 (EBV)).
Interestingly, there were no differences in the decline in
autoab and elevation of BAFF levels, or of anti-EBV-IgG and
anti-VZV-IgG titers, between PV patients with ongoing
clinical remission 12 months after Rtx treatment (9 of 11
patients) and the two PV patients who relapsed at this time
(data not shown).
In addition, the pronounced Rtx-mediated inducing effect
on anti-VZV- and anti-EBV-IgG is illustrated for one
representative PV patient in Figure S1b. This patient showed
a strong increase in both anti-VZV and anti-EBV antibody
titers after B-cell depletion, whereas dsg3-specific autoab
remained unchanged up to 6 months after Rtx treatment
(d210) and decreased slightly afterwards (Figure S1b).
Elevated BAFF levels seem to correlate with raised titers of
pathogen-specific but not of autoreactive IgG antibodies in PV
patients
Figure 5 shows data of all investigated PV patients treated
with Rtx, correlating serum BAFF levels with serum anti-dsg3-
IgG (Figure 5a), anti-VZV (Figure 5b), and anti-EBV (Figure
5c) titers. As the primary end point was defined as alteration
of BAFF and circulating antibody titers immediately after
B-cell depletion, Figure 5 illustrates the relation of serum BAFF
and antibody levels before Rtx treatment and 1 month (d60)
after B-cell-depleting therapy. At this time peripheral B cells
were completely eliminated in all PV patients. In contrast to
autoreactive, dsg3-specific IgG (Figure 5a), elevation of
pathogen-specific anti-VZV- (Figure 5b) and anti-EBV-IgG
(Figure 5c) seemed to be related to strongly increased levels
of circulating BAFF in most of the studied PV patients 1
month after B-cell depletion. Thus, elevated BAFF levels
may possibly exert a differential effect on the production of
dsg3-reactive IgG autoab versus pathogen-specific IgG
antibodies.
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Figure 5. Different effects of B-cell-activating factor (BAFF) on autoreactive versus pathogen-specific antibody titers. Shown is the relation between rituximab-
induced elevation of BAFF and anti-desmoglein 3 (dsg3)-IgG (a), anti-VZV-IgG (b), and anti-EBV-IgG (c) before and 1 month after B-cell-depleting therapy in PV
patients. In contrast to dsg3-specific autoantibodies, which did not show any consistent relation to BAFF (a), elevation of BAFF correlated with increased anti-
VZV- and anti-EBV-IgG in most of the PV patients at this time (b and c). Illustrated are data of all investigated patients, whereas each line represents the data of
one patient. Owing to the broad range of individual (auto)antibody titers, PV patients were divided into two groups regarding their (auto)antibody levels
(Figure 5, left and right). Serum titers of anti-EBV-IgG were available only for 8 of 11 rituximab-treated PV patients (c).
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DISCUSSION
In this study, we investigated the effect of systemic immuno-
suppression alone or in combination with IA or Rtx on the B-
cell-activating factors BAFF and APRIL in 19 PV patients. Upon
treatment with the B-cell-depleting anti-CD20 monoclonal
antibody rituximab, we observed an inverse correlation of
BAFF and relative numbers of peripheral CD19þ B cells.
Rituximab-dependent B-cell depletion induced a dramatic
increase in serum BAFF levels. Moreover, dsg3-specific IgG
autoab titers declined over time, whereas VZV- and EBV-
specific IgG titers showed a statistically significant increase
immediately after Rtx treatment. Elevation of BAFF seems to be
associated with the observed increase in pathogen-specific IgG
antibodies, possibly due to promoting effects of BAFF on
antibody production by long-lived pathogen-specific PC.
In contrast to other B-cell-mediated autoimmune disorders,
such as SLE (Vallerskog et al., 2006) and systemic sclerosis
(Matsushita et al., 2006), overexpression of BAFF or APRIL has
not yet been described in PV. Our present results show that
neither treatment with IS alone nor IS in combination with IA
interferes with serum levels of these two B-cell-activating
factors in PV. Instead, administration of Rtx induces a strong
elevation of BAFF, but not of APRIL. Nonetheless, in contrast to
BAFF, circulating APRIL levels showed a broad variability in PV
patients. Therefore it is possible that therapy-mediated effects
on APRIL could not be detected primarily owing to the small
number of investigated patients.
The increase in BAFF is most likely due to the B-cell-
depleting effect of Rtx as BAFF-R, the main receptor of BAFF,
is mostly expressed on B cells (Schneider and Tschopp, 2003;
Mackay et al., 2007). Thus, elevation of serum BAFF in Rtx-
treated PV patients may partly be explained by its reduced
consumption by B cells. In addition, a direct Rtx-mediated
induction of BAFF through its positive transcriptional regula-
tion was shown in RA, SLE, and primary Sjo¨gren’s syndrome
(Lavie et al., 2007).
As 2 of 11 investigated PV patients on Rtx showed a
clinical relapse 12 months after treatment, a combination of
Rtx with BAFF antagonists may provide a promising
synergistic therapeutic approach for long-term clinical
remission in PV. Mouse models of SLE using lupus-prone
mice showed clinical improvement after administration of
BAFF-R-Fc alone and a total depletion of splenic B
lymphocytes after concomitant treatment with BAFF-R-Fc
and a monoclonal anti-hCD20-antibody (Gong et al., 2005).
Thus, BAFF antagonists, administered with Rtx, probably
operate by depleting B cells more efficiently and for a longer
time owing to the reduced de novo generation of B
lymphocytes. This effect may apply specifically to down-
regulating autoreactive B cells, as very high serum levels of
BAFF, as seen on Rtx, might interfere with the elimination of
autoreactive B cells that are more dependent on BAFF for
survival than non-autoreactive B cells (Lesley et al., 2004;
Thien et al., 2004). Several BAFF antagonists, such as
belimumab, TACI-Ig, BAFF-R-Fc, and AMG 623, are cur-
rently tested in clinical trials (Stohl and Looney, 2006).
Interestingly, a recent study identified anti-BAFF and anti-
APRIL antibodies in two commercial intravenous immuno-
globulin (IVIg) preparations (Le Pottier et al., 2007). As
administration of IVIg is an effective therapeutic approach in
PV (Ahmed, 2001; Segura et al., 2007), a combination
therapy of Rtx and IVIg may act synergistically in down-
regulating the autoimmune response in PV. Recently, a
therapeutic combination of Rtx and IVIg has been shown to
induce a significant clinical improvement in patients with
recalcitrant PV (Ahmed et al., 2006). However, studies
comparing both treatment regimens in PV are still lacking.
In contrast to peripheral B cells expressing both CD20 and
BAFF-R on their surface, long-lived bone-marrow PC are
typically CD20-negative (Silverman and Weisman, 2003;
Stohl and Looney, 2006). Therefore, a direct effect of Rtx on
long-lived PC can be excluded. Possibly, there is an indirect
effect through Rtx-induced elevation of BAFF, probably
mediated by BCMA expression on PC. This hypothesis is
supported by our results showing a statistically significant
elevation of anti-VZV- and anti-EBV-IgG titers in all
investigated rituximab-treated PV patients. Although BAFF
and APRIL bind equally well to BCMA, the increase in
pathogen-specific IgG seen in our PV patients seems to be
most likely mediated by BAFF owing to its significant
induction after Rtx-induced B-cell depletion and the apparent
correlation of increased BAFF levels with increased titers of
pathogen-specific antibodies (Figure 5). This finding is in line
with recent reports demonstrating that BAFF but not APRIL
induces the differentiation of memory marginal zone analog
B cells to PC (Ettinger et al., 2007) and that BAFF enhances
T-cell-dependent humoral immune responses in mice by
increasing antigen-specific PC (Do et al., 2000). Thus, our
observations in PV confirm previous studies reporting
elevated or stable serum IgG titers against tetanus toxoid or
pneumococcal capsular polysaccharide in patients on Rtx
(Cambridge et al., 2003, 2006; Cutler et al., 2006; Eming
et al., 2008; Ferraro et al., 2008).
Recent reports described long-lived (presumably patho-
gen-specific) PC maintaining specific humoral antibody
memory in the absence of persistent antigenic stimulation
in contrast to short-lived (probably autoreactive) PC gener-
ated by persistent antigenic stimulation (Manz et al., 2005;
Browning, 2006; Radbruch et al., 2006). Long-lived bone
marrow PC expressing BCMA have been reported to be
strongly dependent on BAFF for survival through upregulation
of anti-apoptotic Mcl-1 (O’Connor et al., 2004). To our
knowledge, there is no insight into the effect of BAFF on
short-lived PC in B-cell-mediated diseases including PV. As
in humans there is no evidence for differential half-lives of
autoantigen versus pathogen-specific IgG, our data suggest a
differential effect of rituximab and probably of elevated
serum BAFF concentrations on pathogen-specific versus
autoreactive PC possibly due to (i) differences in the
expression of BAFF binding receptors, (ii) direct Rtx-mediated
reduction in short-lived CD20þ plasmablasts/PC, as CD20
expression has been shown in up to 20% of bone marrow PC
(Terstappen et al., 1990; Dorner and Lipsky, 2007), (iii) the
need for T cell help in evolving proliferative B-cell responses
and autoab production, which is impaired after treatment
with anti-CD20 monoclonal antibody (Bouaziz et al., 2007;
www.jidonline.org 2207
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Eming et al., 2008), and (iv) reduction in short-lived PC,
resulting from Rtx-induced depletion of peripheral B cells as
precursors. Finally, elevated antibody production of long-
lived plasma cells, due to directly promoting effects of BAFF
on IgG release by these cells, cannot be excluded.
To our knowledge, the comparison of serum BAFF and
APRIL levels in PV patients on different immunosuppressive
treatment regiments (alone or in combination with IA or Rtx)
is previously unreported. Interestingly, in contrast to com-
monly applied treatment schedules, such as IS and IA, we
found a strong induction of BAFF serum levels with adjuvant
Rtx 1 month after treatment accompanied by upregulation of
pathogen-specific but not of autoreactive IgG. As this was a
monocenter observational cohort study lacking randomiza-
tion and statistical independence, the main objective was
focused on generating a hypothesis. Thus, further multicenter,
randomized trials are mandatory to confirm our present
findings. Further characterization of the possibly different
effects of BAFF on autoreactive versus pathogen-specific PC
will be most helpful to better understand the regulation of
autoreactive PC and autoab in PV.
MATERIALS AND METHODS
Patients
A total of 19 PV patients (8 males, 11 females, mean age: 53±19
years) were included in the present study. Diagnosis of PV was
confirmed by (1) flaccid blisters and erosions of skin and/or mucous
membranes, (2) histopathology revealing suprabasal acantholytic
blisters, (3) direct and indirect immunofluorescence microscopy of
perilesional skin biopsies and of monkey esophagus substrate,
respectively, demonstrating epidermal intercellular IgG and com-
plement deposits, and (4) detection of serum IgG autoab against dsg3
(with/without anti-dsg1 autoab) by ELISA. Patients were divided into
three groups depending on treatment with IS alone, IS with adjuvant
IA, and IS with Rtx. All patients treated with IA or Rtx demonstrated
disease activity refractory to combined systemic immunosuppres-
sives, including high-dose glucocorticoids, and at least one adjuvant
immunosuppressive agent for more than 3 months (Table S1).
According to a consensus statement on definitions of disease, end
points, and therapeutic response for pemphigus (Murrell et al.,
2008), clinical response during follow up was defined as follows: (i)
partial remission: presence of transient new lesions healing within 1
week while the patient is receiving therapy, (ii) complete remission:
absence of new or established lesions while the patient is on therapy,
and (iii) complete remission off therapy: absence of new or
established lesions while the patient is off all systemic therapy for
at least 2 months (Murrell et al., 2008).
Each patient gave written consent prior to inclusion in the study,
which was approved by the Ethics Committee of the Medical Faculty
of Marburg. The study was conducted according to the Declaration
of Helsinki Principles. Fifteen healthy individuals served as controls.
As this was a monocenter observational study, a relatively small
number of PV patients were included in groups I and II (see below),
owing to the rareness of the disease.
Group I: PV patients on immunosuppressive treatment (IS)
Five PV patients (1 male, 4 females, mean age: 53±26 years) were
treated with standard immunosuppressive drugs including high-dose
systemic prednisolone (initial dose: 0.5–1.0mg kg1 per day) and
azathioprine (AZA; 1.5–2.5mg kg1 per day, provided thiopurine-
methyltransferase-activity was normal) or mycophenolate mofetil
(MMF; 2–3 g per day). Depending on the clinical response, the dose
of prednisolone was gradually tapered (Table S1).
Group II: PV patients on IS and adjuvant immunoadsorption
(IA)
Six PV patients (2 males, 4 females, mean age: 52±18 years) who
were resistant to standard immunosuppressive therapy (Table S1)
received adjuvant IA, which is characterized by high-affinity
adsorption of IgG and circulating immune complexes from the
patients’ plasma. Briefly, one treatment cycle consisted of IA on 4
consecutive days. During and after the entire IA treatment, patients
continued to receive immunosuppressive medication (Table S1)
consisting of high-dose systemic prednisolone (initial dose:
0.5–1.0mg kg1 per day) and AZA (1.5–2.5mg kg1 per day) or
MMF (2–3 g per day), according to the extent of the disease (Eming
and Hertl, 2006; Eming et al., 2006).
Group III: PV patients on IS and adjuvant rituximab (Rtx)
This group comprised 11 patients (6 males, 5 females, mean age:
52±17 years) with severe PV defined as at least 30% involvement of
the body surface and/or at least 25% involvement of the oral/genital
mucosa. Furthermore, all patients demonstrated disease activity
refractory to combined systemic immunosuppressives, and three
patients underwent IA prior to Rtx (Table S1). These patients were
included in both the IA and the Rtx groups, so differences between
these groups were not statistically independent. Rituximab
(MabThera, Roche, Grenzach-Wyhlen, Germany) treatment con-
sisted of 4 weekly i.v. infusions of 375mgm2 body surface area on
days 1, 8, 15, and 22. Standard immunosuppressive therapy
included systemic prednisolone (initial dose: 0.5–1.0mg kg1 per
day) and AZA (1.5–2.5mg kg1 per day) or MMF (2–3 g per day).
Prednisolone doses were logarithmically reduced according to the
clinical response. After tapering of prednisolone, AZA or MMF
treatment was continued for an additional 6 months and then
gradually reduced upon long-term clinical remission (Table S1).
Serological and cellular analyses
The numbers of peripheral CD19þ B cells in the studied patients
were determined by flow cytometry and calculated as relative
numbers of B cells, expressed as % of total lymphocytes, at the
Department of Hematology and Immunology. Analysis of VZV- and
EBV-virus capsid-antigen (VCA)-specific IgG was performed by
ELISA and titers were expressed as mIUml1 (VZV) and Uml1 or
nephelometric turbidity units (NTU) in the case of EBV. For detection
of anti-dsg3-IgG autoab, which were expressed as protein index
value in Uml1, sera of the PV patients were subjected to ELISA
(Mesacup Desmoglein-Test, MBL, Naka-ku, Nagoya, Japan). Serum
levels of BAFF (R&D Systems, Wiesbaden-Nordenstadt, Germany)
and APRIL (Bender MedSystems, Vienna, Austria) were also
determined by ELISA according to the manufacturers’ instructions.
All analyses were performed at the following time points: in patients
receiving IS, prior to treatment (d0) and 1 (d30), 3 (d90), and 6 (d180)
months after initiation of immunosuppressive therapy. PV patients
undergoing adjuvant IA were tested prior to (d1) and immediately
after IA (d4) as well as 1 (d30) and 3 (d90) months later. Serum
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samples of Rtx-treated PV patients were analyzed before (d0) and 1
(d60), 3 (d120), 6 (d210), and 12 (d390) months after the final
rituximab infusion, which was given on day 22.
Statistical analysis
The main objective of the study was to investigate the effect of B-
cell-depleting antibody, rituximab, on B-cell-activating factors
(BAFF, APRIL) and antibody titers (anti-dsg3-, anti-VZV-, anti-EBV-
IgG). As the generated data are non-normally distributed, continuous
variables are shown as the median with quartiles and range,
illustrated mostly as box-whisker plots, and non-parametric tests
were used. The box contains 50% of the data (25th and 75th
percentiles), whereas the center line represents the median. The
whiskers restrict the minimum and the maximum of the data set.
Outliers (distance from 25th or 75th percentiles 41.5 length of
the box) are illustrated as points and extreme values (distance from
25th or 75th percentiles 43 length of the box) as asterisks.
Regarding the main objective of this study the immediate impact
of Rtx treatment was of primary interest. Therefore, the primary end
point of this study was alterations in the two B-cell-activating factors
and the three antibody titers at 1 month after initiation of therapy.
For comparison of paired samples of patients before and at different
time points during treatment, the two-sided Wilcoxon signed rank
test was used. Level of significance a was defined as less than 0.05
(Po0.05). The P-values for pairwise comparisons were not adjusted
for multiple testing. Before applying the Wilcoxon signed rank test
Friedman’s test was used as an omnibus test for repeated measures
(paired data).
To support the hypothesis of an effect of Rtx on our target values
the differences in the before/after-analyses were compared to two
commonly applied treatment options, that is, IS and IA. For a
comparison of the three different patient groups before (d0) and 1
month after therapy the Kruskal–Wallis test was performed at first. In
the case of Po0.05, the differences in the two groups, IS and IA,
were compared. Depending on this P-value, P40.05 or Po0.05, the
differences were then compared between Rtx and the pooled data of
IS and IA groups or separately between Rtx and IS and Rtx and IA,
using the two-sided Mann–Whitney U-test.
Statistical analysis was performed using SPSS and GraphPad
Prism.
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SUPPLEMENTARY MATERIAL
Table S1. Patients data before respective treatment (day 0).
Figure S1. Serum levels of B-cell-activating factor (BAFF), a proliferation-
inducing ligand (APRIL), and different antibodies, after immunoadsorption
(IA) and rituximab (Rtx) treatment in a representative pemphigus vulgaris (PV)
patient.
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